A Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants

November 12, 2026 updated by: Trevi Therapeutics

A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Multiple Doses of Quinidine Sulfate, a P-glycoprotein (P-gp) Inhibitor, on the Pharmacokinetics of Nalbuphine Extended-Release Tablets in Healthy Adult Subjects

The primary purpose of this study is to evaluate the effect of quinidine sulfate on the pharmacokinetics (PK) of NAL ER in healthy participants.

Study Overview

Status

Recruiting

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Florida
      • Miami, Florida, United States, 33172
        • Recruiting
        • Clinical Pharmacology of Miami, LLC
        • Contact:
          • Veronica Gomez, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Key Inclusion Criteria:

  • Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kilogram per meter square (kg/m^2) at screening.
  • Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or electrocardiograms (ECGs), as deemed by the principal investigator (PI) or designee.

Exclusion Criteria:

  • History of any diagnosed moderate or severe substance use disorder, other than tobacco use disorder, or a history of or current regular excessive consumption of alcohol.
  • Positive urine drug or alcohol results.
  • Smoker who has smoked or used nicotine containing products within the last 3 months.
  • Clinically significant hypokalemia or hypomagnesemia at the screening visit.
  • History of prolonged QT syndrome.
  • Abnormal liver tests at screening.
  • Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
  • Abnormal estimated glomerular filtration rate (eGFR).

Note: Other inclusion/exclusion criteria mentioned in the protocol may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: NAL ER and Quinidine

Participants will receive NAL ER followed by NAL ER co-administered with quinidine.

Oral tablets

Other Names:
  • Nalbuphine

Oral tablets

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Maximum Plasma Concentration (Cmax) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
Time to Reach Maximum Observed Concentration (Tmax) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUC0-Tlast) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
Apparent Terminal Rate Constant (λz) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
Pre-dose and at multiple timepoints post-dose from Days 1 to 9
Apparent Terminal Half-Life (t1/2) of NAL ER
Time Frame: Pre-dose and at multiple timepoints post-dose from Days 1 to 9
Pre-dose and at multiple timepoints post-dose from Days 1 to 9

Secondary Outcome Measures

Outcome Measure
Time Frame
Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time Frame: Up to Day 19
Up to Day 19

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Chief Development Officer, Trevi Therapeutics

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 3, 2026

Primary Completion (Estimated)

November 30, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe